

# Jodi B Segal

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/11633383/jodi-b-segal-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

74  
papers

4,091  
citations

33  
h-index

63  
g-index

77  
ext. papers

4,837  
ext. citations

4.5  
avg, IF

5.42  
L-index

#	Paper	IF	Citations
74	Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative. <i>Lancet Rheumatology, The</i> , <b>2021</b> ,	14.2	16
73	Geographic Regions Enriched with Frail Older Adults. <i>Journal of the American Medical Directors Association</i> , <b>2021</b> , 22, 2609-2610.e2	5.9	
72	Ultra-Expensive Drugs And Medicare Part D: Spending And Beneficiary Use Up Sharply. <i>Health Affairs</i> , <b>2021</b> , 40, 1000-1005	7	1
71	Dipeptidyl peptidase-4 inhibitor cardiovascular safety in patients with type 2 diabetes, with cardiovascular and renal disease: a retrospective cohort study. <i>Scientific Reports</i> , <b>2021</b> , 11, 16637	4.9	0
70	Treatment of Acute Pain in Adults With Sickle Cell Disease in an Infusion Center Versus the Emergency Department : A Multicenter Prospective Cohort Study. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, 1207-1213	8	2
69	Understanding Geographic Variation in Systemic Overuse Among the Privately Insured. <i>Medical Care</i> , <b>2020</b> , 58, 257-264	3.1	3
68	Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease. <i>PLoS ONE</i> , <b>2020</b> , 15, e0240141	3.7	3
67	Segal and Varadhan Respond to "Estimation With Claims-Based Frailty Indexes". <i>American Journal of Epidemiology</i> , <b>2020</b> , 189, 372	3.8	
66	Association Between Treatment by Fraud and Abuse Perpetrators and Health Outcomes Among Medicare Beneficiaries. <i>JAMA Internal Medicine</i> , <b>2020</b> , 180, 62-69	11.5	7
65	The impact of global budget payment reform on systemic overuse in Maryland. <i>Healthcare</i> , <b>2020</b> , 8, 100475	1.5	1
64	Formulary restrictions may impact enrollment in pragmatic trials and limit generalizability of findings to vulnerable populations. <i>Clinical Trials</i> , <b>2020</b> , 17, 729-731	2.2	1
63	Effect of delays in initiation of adjuvant endocrine therapy on survival among women with breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2020</b> , 184, 965-975	4.4	3
62	Association Between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products. <i>Value in Health</i> , <b>2020</b> , 23, 1599-1605	3.3	3
61	Frailty Among Older Adults With Acute Myocardial Infarction and Outcomes From Percutaneous Coronary Interventions. <i>Journal of the American Heart Association</i> , <b>2019</b> , 8, e013686	6	26
60	Differences in National Diabetes Treatment Patterns and Trends between Older and Younger Adults. <i>Journal of the American Geriatrics Society</i> , <b>2019</b> , 67, 1066-1073	5.6	3
59	Systemic overuse of health care in a commercially insured US population, 2010-2015. <i>BMC Health Services Research</i> , <b>2019</b> , 19, 280	2.9	11
58	Factors associated with potentially inappropriate medication use in community-dwelling older adults in the United States: a systematic review. <i>International Journal of Pharmacy Practice</i> , <b>2019</b> , 27, 408-423	1.7	21

57	Warfarin use and the risk of stroke, bleeding, and mortality in older adults on dialysis with incident atrial fibrillation. <i>Nephrology</i> , <b>2019</b> , 24, 234-244	2.2	14
56	Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2018</b> , 27, 660-667	2.6	10
55	Claims-Based Frailty Index Options. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , <b>2018</b> , 73, 988	6.4	2
54	Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017. <i>Pharmacotherapy</i> , <b>2018</b> , 38, 907-920	5.8	107
53	Treatment of atrial fibrillation with warfarin among older adults with end stage renal disease. <i>Journal of Nephrology</i> , <b>2017</b> , 30, 831-839	4.8	5
52	Frequency and Predictors of Analgesic Prescribing in U.S. Nursing Home Residents with Persistent Pain. <i>Journal of the American Geriatrics Society</i> , <b>2017</b> , 65, 286-293	5.6	31
51	Development of a Claims-based Frailty Indicator Anchored to a Well-established Frailty Phenotype. <i>Medical Care</i> , <b>2017</b> , 55, 716-722	3.1	99
50	Identifying and Prioritizing the Barriers and Facilitators to the Self-Management of Type 2 Diabetes Mellitus: A Community-Centered Approach. <i>Patient</i> , <b>2017</b> , 10, 773-783	3.7	9
49	An Algorithm to Identify Generic Drugs in the FDA Adverse Event Reporting System. <i>Drug Safety</i> , <b>2017</b> , 40, 799-808	5.1	9
48	Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. <i>Annals of Internal Medicine</i> , <b>2017</b> , 166, 637-648	8	383
47	External validation of the claims-based frailty index in the national health and aging trends study cohort. <i>American Journal of Epidemiology</i> , <b>2017</b> , 186, 745-747	3.8	30
46	Patient-relevant outcomes associated with generic tamsulosin, levothyroxine and amphetamine in the FDA Adverse Event Reporting System: a pilot study. <i>Journal of Comparative Effectiveness Research</i> , <b>2017</b> , 6, 437-447	2.1	2
45	Inappropriate Fentanyl Prescribing Among Nursing Home Residents in the United States. <i>Journal of the American Medical Directors Association</i> , <b>2017</b> , 18, 138-144	5.9	15
44	Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis. <i>Annals of Internal Medicine</i> , <b>2016</b> , 164, 740-51	8	364
43	Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: a systematic review and meta-analysis. <i>BMC Nephrology</i> , <b>2016</b> , 17, 157	2.7	56
42	Using Certification to Promote Uptake of Real-World Evidence by Payers. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2016</b> , 22, 191-6	1.9	3
41	Bioequivalence of Biosimilar Tumor Necrosis Factor- $\alpha$ Inhibitors Compared With Their Reference Biologics: A Systematic Review. <i>Annals of Internal Medicine</i> , <b>2016</b> , 165, 565-574	8	39
40	A Framework for Instrument Development of a Choice Experiment: An Application to Type 2 Diabetes. <i>Patient</i> , <b>2016</b> , 9, 465-79	3.7	49

39	Perceived Barriers and Potential Strategies to Improve Self-Management Among Adults with Type 2 Diabetes: A Community-Engaged Research Approach. <i>Patient</i> , <b>2016</b> , 9, 349-58	3.7	12
38	Systematic overuse of healthcare services: a conceptual model. <i>Applied Health Economics and Health Policy</i> , <b>2015</b> , 13, 1-6	3.4	32
37	An index for measuring overuse of health care resources with Medicare claims. <i>Medical Care</i> , <b>2015</b> , 53, 230-6	3.1	22
36	The Association Between Continuity of Care and the Overuse of Medical Procedures. <i>JAMA Internal Medicine</i> , <b>2015</b> , 175, 1148-54	11.5	75
35	Identifying possible indicators of systematic overuse of health care procedures with claims data. <i>Medical Care</i> , <b>2014</b> , 52, 157-63	3.1	40
34	A framework for the analysis of heterogeneity of treatment effect in patient-centered outcomes research. <i>Journal of Clinical Epidemiology</i> , <b>2013</b> , 66, 818-25	5.7	74
33	The state of overuse measurement: a critical review. <i>Medical Care Research and Review</i> , <b>2013</b> , 70, 473-96	3.7	37
32	Systematic assessment of benefits and risks: study protocol for a multi-criteria decision analysis using the Analytic Hierarchy Process for comparative effectiveness research. <i>F1000Research</i> , <b>2013</b> , 2, 160	3.6	9
31	Preliminary competencies for comparative effectiveness research. <i>Clinical and Translational Science</i> , <b>2012</b> , 5, 476-9	4.9	6
30	Determining a definite diagnosis of primary immune thrombocytopenia by medical record review. <i>American Journal of Hematology</i> , <b>2012</b> , 87, 843-7	7.1	11
29	Prevalence of primary immune thrombocytopenia in Oklahoma. <i>American Journal of Hematology</i> , <b>2012</b> , 87, 848-52	7.1	46
28	Impact of bariatric surgery on health care utilization and costs among patients with diabetes. <i>Medical Care</i> , <b>2012</b> , 50, 58-65	3.1	24
27	Validating the adapted Diabetes Complications Severity Index in claims data. <i>American Journal of Managed Care</i> , <b>2012</b> , 18, 721-6	2.1	175
26	Development quality criteria to evaluate nontherapeutic studies of incidence, prevalence, or risk factors of chronic diseases: pilot study of new checklists. <i>Journal of Clinical Epidemiology</i> , <b>2011</b> , 64, 637-57	5.7	88
25	Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. <i>Annals of Internal Medicine</i> , <b>2011</b> , 154, 602-13	8	386
24	Medication utilization and annual health care costs in patients with type 2 diabetes mellitus before and after bariatric surgery. <i>Archives of Surgery</i> , <b>2010</b> , 145, 726-31		75
23	Impact of bariatric surgery on hypertensive disorders in pregnancy: retrospective analysis of insurance claims data. <i>BMJ, The</i> , <b>2010</b> , 340, c1662	5.9	69
22	Reduced incidence of gestational diabetes with bariatric surgery. <i>Journal of the American College of Surgeons</i> , <b>2010</b> , 211, 169-75	4.4	62

21	The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports. <i>American Journal of Hematology</i> , <b>2010</b> , 85, 174-80	7.1	216
20	A systematic review of barriers and interventions to improve appropriate use of therapies for sickle cell disease. <i>Journal of the National Medical Association</i> , <b>2009</b> , 101, 1022-33	2.3	119
19	Prompt reduction in use of medications for comorbid conditions after bariatric surgery. <i>Obesity Surgery</i> , <b>2009</b> , 19, 1646-56	3.7	85
18	Effects of eradication of <i>Helicobacter pylori</i> infection in patients with immune thrombocytopenic purpura: a systematic review. <i>Blood</i> , <b>2009</b> , 113, 1231-40	2.2	210
17	Response: A case of rich fruit. <i>Blood</i> , <b>2009</b> , 113, 6260-6260	2.2	10
16	Outcomes of genetic testing in adults with a history of venous thromboembolism. <i>Evidence Report/technology Assessment</i> , <b>2009</b> , 1-162		5
15	Thrombotic Thrombocytopenic Purpura at Johns Hopkins from 1993 to 2008: Clinical Outcomes and Risk Factors for Relapse in 75 Patients.. <i>Blood</i> , <b>2008</b> , 112, 2288-2288	2.2	
14	Review of the evidence on diagnosis of deep venous thrombosis and pulmonary embolism. <i>Annals of Family Medicine</i> , <b>2007</b> , 5, 63-73	2.9	97
13	Current diagnosis of venous thromboembolism in primary care: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. <i>Annals of Internal Medicine</i> , <b>2007</b> , 146, 454-8	8	66
12	The epidemiology of immune thrombocytopenic purpura. <i>Current Opinion in Hematology</i> , <b>2007</b> , 14, 515-9,3		85
11	Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea. <i>American Journal of Hematology</i> , <b>2006</b> , 81, 927-32	7.1	125
10	Accuracy of CT in the diagnosis of pulmonary embolism: a systematic literature review. <i>American Journal of Roentgenology</i> , <b>2004</b> , 183, 1819-27	5.4	59
9	Accuracy of identification of patients with immune thrombocytopenic purpura through administrative records: a data validation study. <i>American Journal of Hematology</i> , <b>2004</b> , 75, 12-7	7.1	49
8	Usefulness of clinical prediction rules for the diagnosis of venous thromboembolism: a systematic review. <i>American Journal of Medicine</i> , <b>2004</b> , 117, 676-84	2.4	70
7	Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. <i>Annals of Internal Medicine</i> , <b>2003</b> , 139, 1018-33	8	143
6	Testing strategies for diagnosing lupus anticoagulant: decision analysis. <i>American Journal of Hematology</i> , <b>2002</b> , 70, 195-205	7.1	5
5	Validating billing data for RBC transfusions: a brief report. <i>Transfusion</i> , <b>2001</b> , 41, 530-3	2.9	43
4	Autologous blood transfusion in the United States: clinical and nonclinical determinants of use. <i>Transfusion</i> , <b>2001</b> , 41, 1539-47	2.9	33

3	Limited evidence for the benefits of anticoagulation treatment for non-rheumatic atrial fibrillation. <i>Evidence-Based Healthcare and Public Health</i> , <b>2001</b> , 5, 79-80		
2	Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs. <i>Journal of General Internal Medicine</i> , <b>2000</b> , 15, 56-67	4	96
1	Thiazolidinedione use and risk of hospitalization for pneumonia in type 2 diabetes: [population based matched case-control study. <i>F1000Research</i> , <b>2</b> , 145	3.6	1